Trial Profile
Induction With Complement Inhibitor Eculizumab in Clinical Islet Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Transplant rejection
- Focus Therapeutic Use
- Acronyms ICC
- 03 Oct 2018 Status changed from recruiting to completed.
- 18 May 2017 Status changed from not yet recruiting to recruiting.
- 06 Apr 2016 New trial record